NO20080051L - Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme - Google Patents

Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme

Info

Publication number
NO20080051L
NO20080051L NO20080051A NO20080051A NO20080051L NO 20080051 L NO20080051 L NO 20080051L NO 20080051 A NO20080051 A NO 20080051A NO 20080051 A NO20080051 A NO 20080051A NO 20080051 L NO20080051 L NO 20080051L
Authority
NO
Norway
Prior art keywords
piperazinyl
methoxyphenyl
propoxy
dichloro
methoxy
Prior art date
Application number
NO20080051A
Other languages
English (en)
Norwegian (no)
Inventor
Gregg Brian Feigelson
Henry Lee Strong
Hong Wen
Marc Sadler Tesconi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080051(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20080051L publication Critical patent/NO20080051L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20080051A 2005-07-01 2008-01-04 Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme NO20080051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01
PCT/US2006/025160 WO2007005462A1 (en) 2005-07-01 2006-06-28 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same

Publications (1)

Publication Number Publication Date
NO20080051L true NO20080051L (no) 2008-01-29

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080051A NO20080051L (no) 2005-07-01 2008-01-04 Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme

Country Status (24)

Country Link
US (2) US7767678B2 (pl)
EP (1) EP1902029B2 (pl)
JP (1) JP2009500332A (pl)
KR (1) KR20080028386A (pl)
CN (1) CN101248047A (pl)
AR (1) AR054505A1 (pl)
AU (1) AU2006266045A1 (pl)
BR (1) BRPI0613574A2 (pl)
CA (1) CA2613053C (pl)
CR (1) CR9596A (pl)
DK (1) DK1902029T4 (pl)
EC (1) ECSP078063A (pl)
ES (1) ES2449197T5 (pl)
GT (1) GT200600282A (pl)
IL (1) IL188483A0 (pl)
MX (1) MX2008000384A (pl)
NO (1) NO20080051L (pl)
PA (1) PA8685101A1 (pl)
PE (1) PE20070190A1 (pl)
PL (1) PL1902029T5 (pl)
PT (1) PT1902029E (pl)
RU (1) RU2007148072A (pl)
TW (1) TW200740797A (pl)
WO (1) WO2007005462A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1015941A2 (pt) * 2009-07-02 2016-04-19 Wyeth Llc formulações de comprimido de 3-cianoquinolina e uso das mesmas.
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
WO2015123758A1 (en) * 2014-02-20 2015-08-27 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
LT3555097T (lt) 2016-12-16 2022-08-25 Janssen Pharmaceutica Nv Imidazo[4,5-d]pirolo[2,3-b]piridino junginiai kaip janus kinazės inhibitoriai
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法
BR112023018286A2 (pt) 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
AU2004267061A1 (en) * 2003-08-19 2005-03-03 Wyeth Holdings Corporation Process for the preparation of 4-amino-3-quinolinecarbonitriles
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
AU2003291245A1 (en) * 2003-11-06 2004-06-06 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
CN101252931A (zh) * 2005-06-24 2008-08-27 惠氏公司 用于治疗癌症的4-苯胺基-3-喹啉甲腈
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
PL1902029T3 (pl) 2014-08-29
IL188483A0 (en) 2008-04-13
US20070015767A1 (en) 2007-01-18
DK1902029T3 (en) 2014-02-17
AR054505A1 (es) 2007-06-27
EP1902029B2 (en) 2022-02-16
CA2613053C (en) 2015-11-24
HK1114614A1 (en) 2008-11-07
KR20080028386A (ko) 2008-03-31
DK1902029T4 (da) 2022-02-28
BRPI0613574A2 (pt) 2016-11-16
EP1902029B1 (en) 2014-01-08
US20100324066A1 (en) 2010-12-23
CA2613053A1 (en) 2007-01-11
CR9596A (es) 2008-03-06
PL1902029T5 (pl) 2022-08-29
US8445496B2 (en) 2013-05-21
PT1902029E (pt) 2014-03-05
WO2007005462A1 (en) 2007-01-11
ECSP078063A (es) 2008-01-23
EP1902029A1 (en) 2008-03-26
RU2007148072A (ru) 2009-08-10
CN101248047A (zh) 2008-08-20
MX2008000384A (es) 2008-03-07
ES2449197T3 (es) 2014-03-18
JP2009500332A (ja) 2009-01-08
GT200600282A (es) 2007-02-14
AU2006266045A1 (en) 2007-01-11
TW200740797A (en) 2007-11-01
PE20070190A1 (es) 2007-03-20
ES2449197T5 (es) 2022-04-28
PA8685101A1 (es) 2007-01-17
US7767678B2 (en) 2010-08-03

Similar Documents

Publication Publication Date Title
NO20080051L (no) Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme
NO20080820L (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20081454L (no) Met-kinaseinhibitorer
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
MX2010005556A (es) Procedimiento para la fabricacion de un derivado de indolinona.
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
NO20082598L (no) ERBB-inhibitorer
MX2007002521A (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
NO20084307L (no) Heterocykliske GPCR agonister
WO2008011130A8 (en) Amide compounds
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20074188L (no) Prosess for fremstilling av montelukast og mellomprodukter for det
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
NO20082118L (no) Heterocykliske CETP-inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application